Key result
PAH-targeted therapies such as riociguat demonstrated significant improvement in walking distance in patients with non-operable chronic thromboembolic pulmonary hypertension.
Why the study?
Do PAH-targeted therapies improve walking distance in patients with non-operable chronic thromboembolic pulmonary hypertension?
Population
Patients with chronic thromboembolic pulmonary hypertension, particularly non-operable patients or those…
Design
Review
Authors
Loading...
May support riociguat consideration in non-operable CTEPH; leaves open need for randomized confirmation.
Do PAH-targeted therapies improve walking distance in patients with non-operable chronic thromboembolic pulmonary hypertension?
Riociguat, but not bosentan, has demonstrated significant improvement in walking distance for non-operable CTEPH, highlighting the potential role of specific PAH-targeted medical therapies in this population.
Pepke‐Żaba et al. (2013) conducted a review in Chronic thromboembolic pulmonary hypertension (CTEPH). PAH-targeted therapies was evaluated. PAH-targeted therapies such as riociguat demonstrated significant improvement in walking distance in patients with non-operable chronic thromboembolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: